Sedative/hypnotic drugs
The main drugs in this group are benzodiazepines, but chloral derivatives ( three weeks (but can last up to two months) before it returns to prewithdrawal levels, and it is commonly termed "rebound insomnia." This is an appropriate term if the insomnia is not as pronounced as it was before the treatment started, but is better described as "recoil" or "overshoot" insomnia ifit is severe and leads to fewer hours of sleep than before the drug was taken.
Rebound and recoil insomnia.
In addition to further insomnia, patients also experience other symptoms during the day including anxiety and its bodily manifestations ( Often the first evidence of dependence on hypnotic drugs is noticed during withdrawal. As dependence, once established, is difficult to treat, it is better to anticipate problems of withdrawal wherever possible. By assessing the various factors that contribute to dependence, both the duration of drug treatment and the mode of withdrawal can be selected to minimise symptoms.
Most of the factors that contribute to dependence have already been discussed. In general, the greater the amount of drug taken and the more rapidly it is withdrawn the greater the risk of dependence.
The influence of personality is also important. Patients with dependent personalities rely to a large extent on external forms of support including people and drugs, and when this support is withdrawn they have great difficulty in adjustment. Such patients often rely a great deal on their medical attendants (particularly their general practitioners) for such support and are sometimes described as "fat folder" patients because of the impressive width of their medical records. It is sometimes (accurately) said that the single most important factor in withdrawing a patient from dependency on hypnotic drugs is the relationship between the patient and the doctor. Though rebound phenomena are neurophysiologically universal, certain patients are more prone to develop greater dependence on hypnotic drugs. Only about 30% to 40% of patients experience clinical problems in the form of withdrawal symptoms. New symptoms can also arise after a drug has been stopped, which are unrelated to its pharmacological actions ("pseudowithdrawal" symptoms) . This is an example of the nocebo effect (nocebo=I will harm), the converse of the placebo effect. As public awareness of problems of withdrawal after taking tranquillising and hypnotic drugs increases, the nocebo effect assumes greater importance and complicates the interpretation of withdrawal symptoms.
The simplest form of withdrawal programme is gradual withdrawal over a period varying from two weeks to many months. This permits adaptive changes to take place in the central nervous system that reduce the perturbation of withdrawal. The reduction can be supervised by the clinician or in some cases left primarily to the patient (though monitored medically through review of prescriptions). If reduction is planned over a long period (for example, six to 12 months) it is preferable for the patient to take the main role in planning the programme unless there is additional help from other therapists, including psychologists, community nurses, psychiatrists, and self help organisations. Formal withdrawal programmes can include yoga, meditation, hypnotherapy, and cognitive therapy; these non-pharmacological treatments of insomnia can help to counteract the severity of withdrawal symptoms as well as promoting sleep in their own right.
Although rebound and recoil insomnia last for a period of only one to three weeks, problems often continue after this time. These cannot be described easily in the language of pharmacological dependence, because they can last for up to nine months after withdrawal. There is evidence that this "postwithdrawal" syndrome is the result of a delay in neurophysiological adjustment after withdrawal of a drug, during which there is reappraisal of the perception of threat. In other words, the patient has to relearn how to cope with stress and is unsettled while this is taking place.
If insomnia persists after this period both clinician and patient are faced with a difficult decision. If drug treatment is reinstituted it is likely to be long term or permanent. While this option is not attractive it may be the only realistic one in some cases, and can be chosen when the benefits achieved are greater than the consequences of dependence. Main features of postwithdrawal syndrome * Persistence of insomnia more than eight weeks after complete withdrawal * Greater vulnerability to stress * Anxiety and irritability during the day * Temporary resolution with benzodiazepines
